A phase I study of vaccination with lethally irradiated, autologous acute myeloblastic leukemia cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor in patients with advanced myelodysplasia or acute myelogenous leukemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GM-CSF-transduced tumour cell vaccine (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions

Most Recent Events

10 Mar 2011 Biomarkers information updated
27 Dec 2007 The expected completion date for this trial is now 1 Mar 2006.
27 Dec 2007 Status change from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight